cancer resistance

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

Activation of retrotransposons in the animals’ cancerous cells sets off an innate immune response that triggers cell death.

The largest study to date of the animals’ genetics provides robust evidence that they are adapting to survive a highly lethal, contagious cancer scientists feared would cause their extinction.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.

In mice, the tumor cells are able to thwart the immune response that would kill them—but immunotherapy prevented the return of melanoma.

Researchers unravel the sophisticated ways cancers evade treatments, including immunotherapies, designed to destroy them.

Cancers appear to be able to evolve resistance to many of the therapies doctors have tried.

Two captive males of the cancer-resistant species have shown signs of malignant tumors.

Two studies reveal that the giant mammals have dozens of extra copies of a cancer-preventing gene.